NEW YORK, July 18 – Ventana Medical Systems said Wednesday that GlaxoSmithKline has chosen its Discovery in situ hybridization and immunohistochemistry system for use in DNA and protein expression experiments.

GlaxoSmithKline will install six to eight of Ventana’s systems in its European and North American research facilities, Ventana CEO Christopher Gleeson told GenomeWeb. The two companies will also collaborate to develop improvements in tissue gene expression profiling methods.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.